Table 3.
Associations between baseline urinary F2-isoprostane metabolites and percentage of weight change by follow-up periods
| Biomarker | At 7-year follow-up |
At 10-year
follow-up |
At 15-year
follow-up |
|||
|---|---|---|---|---|---|---|
| β (95% CI) a | P value | β (95% CI) a | P value | β (95% CI) a | P value | |
| F2-IsoP-M | ||||||
| Q1 | Reference | Reference | Reference | |||
| Q2 | 0.15 (−0.99, 1.29) | 0.80 | 0.28 (−1.19, 1.75) | 0.71 | −0.97 (−2.43, 0.48) | 0.19 |
| Q3 | −0.84 (−2.00, 0.33) | 0.16 | 0.05 (−1.45, 1.55) | 0.95 | −1.67 (−3.15, −0.18) | 0.03 |
| Q4 | −1.18 (−2.37, 0.01) | 0.05 | −1.35 (−2.89, 0.18) | 0.08 | −1.61 (−3.17, −0.05) | 0.04 |
| P for trend b | 0.02 | 0.04 | 0.05 | |||
| Continuous (log2) | −0.50 (−1.05, 0.05) | 0.07 | −0.44 (−1.14, 0.27) | 0.23 | −0.82 (−1.53, −0.12) | 0.02 |
| F2-IsoP-M to F2-IsoPs ratio | ||||||
| Q1 | Reference | Reference | Reference | |||
| Q2 | 0.20 (−0.95, 1.35) | 0.73 | −0.30 (−1.77, 1.17) | 0.69 | 0.03 (−1.44, 1.50) | 0.97 |
| Q3 | 0.04 (−1.12, 1.19) | 0.95 | −1.56 (−3.06, −0.06) | 0.04 | −1.57 (−3.07, −0.07) | 0.04 |
| Q4 | −0.16 (−1.33, 1.02) | 0.79 | −0.90 (−2.40, 0.61) | 0.24 | −1.68 (−3.21, −0.15) | 0.03 |
| P for trend b | 0.68 | 0.21 | 0.01 | |||
| Continuous (log2) | −0.23 (−0.69, 0.23) | 0.33 | −0.46 (−1.05, 0.13) | 0.12 | −0.61 (−1.21, −0.02) | 0.04 |
a
Multivariable adjusted for age at baseline, height, education, cigarette smoking, physical activity, menopausal status, regular use of vitamin supplements, Charlson comorbidity score and total energy intake, as well as use of antibiotics, vitamin supplements and NSAIDs in 24 hours before sample collection.
b
Statistical tests for trend were conducted by entering the median of each quartile into the model as continuous variables.